Axon 1419
CAS [1048007-93-7]
MF C28H30N6OS.CH4O3SMW 594.75
P Dubreuil et al. Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT. Plos ONE 2009, 4(9), e7258. |
BN Bui et al. Preliminary efficacy and safety results of masitinib administered, front line in patients with advanced GIST. A phase II study. J. Clin. Onco. 2007, 25(18S), 10025. |
G Giamas et al. Protein kinases as targets for cancer treatment. Pharmacogenomics. 2007, 8(8), 1005-1016. |
KA Hahn et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J. Vet. Intern. Med. 2008, 22(6), 1301-1309. |
4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide methanesulfonate
[790299-79-5]
Axon Medchem的业务之一,是独有的Axon Ligands配体库,在世界范围内,被认为是药物研发的标准。这其中,针对850余种生物靶标(包括细胞信号、基因转录、凋亡、细胞周期调控、CNS等),Axon Medchem拥有多达2000余种小分子抑制剂或调节剂。除了配体库,Axon Medchem还是欧洲著名的CRO公司,主要针对生物活性分子和药物类似分子展开合成及协议开发工作,在过去的10年中,Axon Medchem已经发现了多种潜在药物分子,并在生物医药界享有一定的声誉。